Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Biomatics Closes Second VC Fund; SVB Buys Leerink To Expand Life Science Services

Executive Summary

Scrip spoke with Managing Director Julie Sunderland about Biomatics' new $300m fund. Also, Silicon Valley Bank reveals its surprising Leerink buy, Perceptive Advisors raises $675m, Roivant brings in another $200m, and cell and gene therapy financings surge in the third quarter.

Advertisement

Related Content

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs
Newly Hatched Mirum To Focus On Rare Liver Disease Candidates Shelved By Shire
Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group
Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m
Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies
Finance Watch: Bicycle Spins Toward Clinic With $52m Round; Stock Spikes Spur Offerings
Finance Watch: Two New VC Funds Raise $500m; One New US IPO; And Galena's 'Strategic Review'
VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth
Immuno-Oncology Startup Snatches $67m In Series A
Venture Funding Deals, June 2015

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124185

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel